Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Anesiva Loses Adlea, Zingo Painkillers From Market

This article was originally published in PharmAsia News

Executive Summary

A Phase III trial failed to support India-based Anesiva's Adlea (capsaicin) painkiller at the same time the firm said it would withdraw another painkiller, Zingo (lidocaine), from the U.S. market. The twin moves, according to an analyst, endanger the company's financial future. The trial showed Adlea failed to meet the main goal of the trial, Anesiva said. It withdrew Zingo because of problems with the shelf life of the drug caused by manufacturing difficulties, Anesiva said. The company said it still seeks to form a partnership with another firm on both drugs. Resurrecting Zingo would take at least a year and millions of dollars, the analyst said. (Click here for more

You may also be interested in...



QUOTED. 26 October. Scott Rabuka.

For the first time, the US FDA granted an emergency use authorization to a device that allows for the home collection of saliva for COVID-19 diagnosis. See what Scott Rabuka, senior director of molecular products at DNA Genotek, which developed the test, said about it here.

L’Oreal Names CEO To Follow Agon; ELC And Coty Appoint Digital Leadership; Executive News In Brief

Deputy CEO Nicolas Hieronimus will take L’Oreal’s helm beginning in May 2021, with Jean-Paul Agon continuing as chairman, the firm announced on 14 October. The Estee Lauder Companies hires PepsiCo’s Gibu Thomas to lead its online business, and Coty appoints its first chief digital officer.

Speedy Approval Of Gilead’s Veklury Sets Stage For Pediatric Expansion, Dosing Refinement

US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel